Plasma 25-hydroxyvitamin D and colorectal cancer risk according to tumour immunity status

Gut

Volumn 65, Issue 2, 2016, Pages 296-304

  Song, Mingyang ^a   Nishihara, Reiko ^a,b   Wang, Molin ^a   Chan, Andrew T ^b,c   Qian, Zhi Rong ^b   Inamura, Kentaro ^b,d   Zhang, Xuehong ^b   Ng, Kimmie ^b   Kim, Sun A ^b   Mima, Kosuke ^b   Sukawa, Yasutaka ^b   Nosho, Katsuhiko ^e   Fuchs, Charles S ^b   Giovannucci, Edward L ^a,b   Wu, Kana ^a   Ogino, Shuji ^a,b,f  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; CD45RO ANTIGEN; TRANSCRIPTION FACTOR FOXP3; 25-HYDROXYVITAMIN D; C REACTIVE PROTEIN; CD3 ANTIGEN; INTERLEUKIN 6; TUMOR NECROSIS FACTOR; VITAMIN D;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CANCER RISK; CASE CONTROL STUDY; CD3+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DENSITY; COLORECTAL CANCER; COLORECTAL CARCINOMA; CONTROLLED STUDY; CPG ISLAND; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; MIDDLE AGED; OUTCOME ASSESSMENT; PHENOTYPE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY; ANALOGS AND DERIVATIVES; BLOOD; CELL COUNT; COLORECTAL NEOPLASMS; CYTOLOGY; DATA BASE; IMMUNOLOGY; REGRESSION ANALYSIS; T LYMPHOCYTE;

ADULT; AGED; ANTIGENS, CD3; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CELL COUNT; COLORECTAL NEOPLASMS; DATABASES AS TOPIC; FEMALE; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; REGRESSION ANALYSIS; T-LYMPHOCYTES; TUMOR NECROSIS FACTORS; VITAMIN D;

EID: 84958863200     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2014-308852     Document Type: Article

References (52)

1. Ma Y, Zhang P, Wang F, et al. Association between vitamin D and risk of colorectal cancer: a systematic review of prospective studies. J Clin Oncol 2011;29:3775-82.
2. Feldman D, Krishnan AV, Swami S, et al. The role of vitamin D in reducing cancer risk and progression. Nat Rev Cancer 2014;14:342-57.
3. Liu PT, Stenger S, Li H, et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 2006;311:1770-3.
4. Edfeldt K, Liu PT, Chun R, et al. T-cell cytokines differentially control human monocyte antimicrobial responses by regulating vitamin D metabolism. Proc Natl Acad Sci USA 2010;107:22593-8.
5. Sigmundsdottir H, Pan J, Debes GF, et al. DCs metabolize sunlight-induced vitamin D3 to 'program' T cell attraction to the epidermal chemokine CCL27. Nat Immunol 2007;8:285-93.
6. Adams JS, Hewison M. Unexpected actions of vitamin D: new perspectives on the regulation of innate and adaptive immunity. Nat Clin Pract Endocrinol Metab 2008;4:80-90.
7. Veldhoen M, Brucklacher-Waldert V. Dietary influences on intestinal immunity. Nat Rev Immunol 2012;12:696-708.
8. Fridman WH, Pages F, Sautes-Fridman C, et al. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2012;12:298-306.
9. Xia D, Wang D, Kim SH, et al. Prostaglandin E2 promotes intestinal tumor growth via DNA methylation. Nat Med 2012;18:224-6.
10. Marzbani E, Inatsuka C, Lu H, et al. The invisible arm of immunity in common cancer chemoprevention agents. Cancer Prev Res (Phila) 2013;6:764-73.
11. Galon J, Mlecnik B, Bindea G, et al. Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J Pathol 2014;232:199-209.
12. Di Caro G, Marchesi F, Laghi L, et al. Immune cells: plastic players along colorectal cancer progression. J Cell Mol Med 2013;17:1088-95.
13. Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol 2013;14:1014-22.
14. Rocca YS, Roberti MP, Arriaga JM, et al. Altered phenotype in peripheral blood and tumor-associated NK cells from colorectal cancer patients. Innate Immun 2013;19:76-85.
15. Nosho K, Baba Y, Tanaka N, et al. Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review. J Pathol 2010;222:350-66.
16. Ogino S, Nosho K, Irahara N, et al. Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype. Clin Cancer Res 2009;15:6412-20.
17. Liao X, Lochhead P, Nishihara R, et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med 2012;367:1596-606.
18. Wu K, Feskanich D, Fuchs CS, et al. A nested case control study of plasma 25-hydroxyvitamin D concentrations and risk of colorectal cancer. J Natl Cancer Inst 2007;99:1120-9.
19. Hollis BW. Quantitation of 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D by radioimmunoassay using radioiodinated tracers. Methods Enzymol 1997;282:174-86.
20. Song M, Wu K, Ogino S, et al. A prospective study of plasma inflammatory markers and risk of colorectal cancer in men. Br J Cancer 2013;108:1891-8.
21. Chan AT, Ogino S, Giovannucci EL, et al. Inflammatory markers are associated with risk of colorectal cancer and chemopreventive response to anti-inflammatory drugs. Gastroenterology 2011;140:799-808.
22. Chan AT, Ogino S, Fuchs CS. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med 2007;356:2131-42.
23. Nosho K, Irahara N, Shima K, et al. Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample. PLoS ONE 2008;3:e3698.
24. Ogino S, Nosho K, Kirkner GJ, et al. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 2009;58:90-6.
25. Ogino S, Kawasaki T, Brahmandam M, et al. Precision and performance characteristics of bisulfite conversion and real-time PCR (MethyLight) for quantitative DNA methylation analysis. J Mol Diagn 2006;8:209-17.
26. Lunn M, McNeil D. Applying Cox regression to competing risks. Biometrics 1995;51:524-32.
27. Cochran WG. The combination of estimates from different experiments. Biometrics 1954;10:101-29.
28. Ghashut RA, Talwar D, Kinsella J, et al. The effect of the systemic inflammatory response on plasma vitamin 25 (OH) D concentrations adjusted for albumin. PLoS ONE 2014;9:e92614.
29. Zhou B, Shu B, Yang J, et al. C-reactive protein, interleukin-6 and the risk of colorectal cancer: a meta-analysis. Cancer Causes Control 2014;25:1397-405.
30. Bishehsari F, Mahdavinia M, Vacca M, et al. Epidemiological transition of colorectal cancer in developing countries: environmental factors, molecular pathways, and opportunities for prevention. World J Gastroenterol 2014;20:6055-72.
31. Colussi D, Brandi G, Bazzoli F, et al. Molecular pathways involved in colorectal cancer: implications for disease behavior and prevention. Int J Mol Sci 2013;14:16365-85.
32. Galon J, Pages F, Marincola FM, et al. Cancer classification using the Immunoscore: a worldwide task force. J Transl Med 2012;10:205.
33. Li P, Wu H, Zhang H, et al. Aspirin use after diagnosis but not prediagnosis improves established colorectal cancer survival: a meta-analysis. Gut 2015;64:1419-25.
34. Alexander J, Watanabe T, Wu TT, et al. Histopathological identification of colon cancer with microsatellite instability. Am J Pathol 2001;158:527-35.
35. Koshiol J, Lin SW. Can tissue-based immune markers be used for studying the natural history of cancer? Ann Epidemiol 2012;22:520-30.
36. Grizzi F, Bianchi P, Malesci A, et al. Prognostic value of innate and adaptive immunity in colorectal cancer. World J Gastroenterol 2013;19:174-84.
37. Palmqvist R, Wikberg ML, Ling A, et al. The association of immune cell infiltration and prognosis in colorectal cancer. Curr Colorectal Cancer Rep 2013;9:372-9.
38. Dahlin AM, Henriksson ML, Van Guelpen B, et al. Colorectal cancer prognosis depends on T-cell infiltration and molecular characteristics of the tumor. Mod Pathol 2011;24:671-82.
39. Wactawski-Wende J, Kotchen JM, Anderson GL, et al. Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med 2006;354:684-96.
40. Ogino S, Galon J, Fuchs CS, et al. Cancer immunology - analysis of host and tumor factors for personalized medicine. Nat Rev Clin Oncol 2011;8:711-19.
41. Ahn J, Sinha R, Pei Z, et al. Human gut microbiome and risk for colorectal cancer. J Natl Cancer Inst 2013;105:1907-11.
42. Kostic AD, Gevers D, Pedamallu CS, et al. Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res 2012;22:292-8.
43. Lemire JM, Archer DC, Beck L, et al. Immunosuppressive actions of 1,25-dihydroxyvitamin D3: preferential inhibition of Th1 functions. J Nutr 1995;125:1704S-8S.
44. Boonstra A, Barrat FJ, Crain C, et al. 1alpha,25-Dihydroxyvitamin d3 has a direct effect on naive CD4(+) T cells to enhance the development of Th2 cells. J Immunol 2001;167:4974-80.
45. von Essen MR, Kongsbak M, Schjerling P, et al. Vitamin D controls T cell antigen receptor signaling and activation of human T cells. Nat Immunol 2010;11:344-9.
46. Meeker S, Seamons A, Paik J, et al. Increased dietary vitamin D suppresses MAPK signaling, colitis and colon cancer. Cancer Res 2014;74:4398-408.
47. Ogino S, Stampfer M. Lifestyle factors and microsatellite instability in colorectal cancer: the evolving field of molecular pathological epidemiology. J Natl Cancer Inst 2010;102:365-7.
48. Ogino S, Chan AT, Fuchs CS, et al. Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field. Gut 2011;60:397-411.
49. Hoffmeister M, Blaker H, Kloor M, et al. Body mass index and microsatellite instability in colorectal cancer: a population-based study. Cancer Epidemiol Biomarkers Prev 2013;22:2303-11.
50. Hughes LA, Khalid-de Bakker CA, Smits KM, et al. The CpG island methylator phenotype in colorectal cancer: progress and problems. Biochimica et biophysica acta 2012;1825:77-85.
51. Epplein M, Bostick RM, Mu L, et al. Challenges and opportunities in international molecular cancer prevention research: an ASPO molecular epidemiology and the environment and international cancer prevention interest groups report. Cancer Epidemiol Biomarkers Prev 2014;23:2613-17.
52. Campbell PT, Deka A, Briggs P, et al. Establishment of the cancer prevention study II nutrition cohort colorectal tissue repository. Cancer Epidemiol Biomarkers Prev 2014;23:2694-702.